Washington: Joe Biden's scientific advisers will meet with vaccine makers in coming days as the presidential transition remains stalled because of President Donald Trump's refusal to acknowledge that he lost the election.
That delayed handoff to the next administration is especially problematic during a public health crisis, the government's top infectious disease expert said.
Of course, it would be better if we could start working with them, said Dr Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases who has been through many presidential transitions during 36 years of government service.
He likened the process to runners passing on the baton in a relay race. You don't want to stop, he said.
The president-elect's outreach to the vaccine manufacturers comes as the coronavirus pandemic in the United States has entered perhaps its most dangerous phase.
The seven-day rolling average for new daily cases stood at 145,400 on Saturday, according to data from Johns Hopkins University. That means the U.S. is adding about 1 million new cases a week, and deaths averaged 820 a day, a 33% increase in just two weeks.
"We're going to start those consultations this week said Biden's chief of staff, Ron Klain, citing Pfizer and other pharmaceutical companies.
Also Read:What mandate? Biden's agenda faces a divided Congress